Q2 2025 Management View CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, ...

ResMed Inc (RMD) reports a 10% revenue increase and significant margin expansion, driven by robust device sales and strategic ...

ResMed noted that patient adoption of the myAir app continues to be strong. The adoption rates of myAir app by new patients set up on therapy with AirSense 11 continue to be more than double that ...

UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

(Image Credits: Pixabay) ResMed on Tuesday announced that it has launched AirSense 11 in India. According to the company’s statement, it is the next-generation Continuous Positive Airway ...

ResMed (ASX: RMD) posted a solid December quarter, with most figures slightly exceeding market expectations, driven by strong ...